Back to search

Article

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

2022-02-15

Abstract excerpt

Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate a third vaccination with MVA-MERS-S in a subgroup of trial participants one...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9692a98b-105b-53c8-80e6-ca19465153a2
DOI
10.1101/2022.02.14.22270168
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndromeDOI 10.1101/2022.02.14.22270168
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled TrialSemantic proximity
Evaluation of candidate vaccine approaches for MERS-CoVSemantic proximity
Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimenSemantic proximity
A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in AdultsSemantic proximity
Immunogenicity of DNA vaccine encoding spike protein against Middle East respiratory syndrome coronavirus in mammalian modelSemantic proximity
Second Boost of Omicron SARS-CoV-2 S1 Subunit Vaccine Induced Broad Humoral Immune Responses in Elderly MiceSemantic proximity
The Efficacy for the Booster Dose of Covid-19 Vaccine between Sars-Cov-2 Omicron Variant and a Two-Year Longitudinal Antibody on Wild Type ConvalescentsSemantic proximity
A Phase I, Prospective, Randomized, Open-Labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in AdultsSemantic proximity
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccinationSemantic proximity
Longitudinal analysis of B- and T-cell responses to SARS-CoV-2 recombinant S-protein vaccine S-268019-b in phase 1/2 priming and booster studySemantic proximity
Phase 1 Study of Safety, Reactogenicity, and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized AdultsSemantic proximity
Prime-boost protein subunit vaccines against SARS-CoV-2 are highly immunogenic in mice and macaquesSemantic proximity
Select a neighboring publication to make it the new centre.